Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor

Blood

Volumn 118, Issue 15, 2011, Pages 4179-4187

  Bhattacharya, Sabyasachi ^a   Zheng, Hui ^a   Tzimas, Christos ^a   Carroll, Martin ^b   Baker, Darren P ^c   Fuchs, Serge Y ^a  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; ALPHA INTERFERON; BCR ABL PROTEIN; IMATINIB; POLYCYSTIN 2; SHORT HAIRPIN RNA; STAT1 PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ATTENUATION; CANCER GROWTH; CANCER INHIBITION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFICACY; HELA CELL; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LEUKEMIA CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

EID: 80054122595     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-12-325373     Document Type: Article

References (50)

1. Burke BA, Carroll M. BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogenous leukemia. Leukemia. 2010;24(6):1105-1112.
2. Kharas MG, Fruman DA. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res. 2005;65(6):2047-2053. (Pubitemid 40490106)
3. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172-183. (Pubitemid 40314949)
4. Branford S, Rudzki Z, Harper A, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 2003; 17(12):2401-2409. (Pubitemid 38072578)
5. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11): 994-1004. (Pubitemid 36302244)
6. Kantarjian HM, O'Brien S, Cortes J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosomepositive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer. 2003;98(12):2636-2642. (Pubitemid 37509527)
7. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105(7): 2640-2653. (Pubitemid 40446252)
8. Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99(1): 319-325.
9. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003;101(12):4701-4707. (Pubitemid 36857723)
10. Elrick LJ, Jorgensen HG, Mountford JC, Holyoake TL. Punish the parent not the progeny. Blood. 2005;105(5):1862-1866. (Pubitemid 40731765)
11. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006; 107(11):4532-4539. (Pubitemid 43801382)
12. Angstreich GR, Matsui W, Huff CA, et al. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br J Haematol. 2005;130(3):373-381. (Pubitemid 43899585)
13. Kujawski LA, Talpaz M. The role of interferonalpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev. 2007;18(5-6): 459-471. (Pubitemid 47302836)
14. Carella AM. Interferon-alpha is able to maintain complete molecular remission induced by imatinib after its discontinuation. Leukemia. 2008; 22(5):1090-1091. (Pubitemid 351689904)
15. Alimena G, Breccia M, Luciano L, et al. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate. Leuk Res. 2008; 32(2):255-261. (Pubitemid 351215539)
16. Taniguchi T, Takaoka A. A weak signal for strong responses: interferon-alpha/beta revisited. Nat Rev Mol Cell Biol. 2001;2(5):378-386. (Pubitemid 33674050)
17. Aaronson DS, Horvath CM. A road map for those who know JAK-STAT. Science. 2002;296(5573): 1653-1655. (Pubitemid 34579157)
18. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem. 1998;67:227-264. (Pubitemid 28411130)
19. Platanias LC. Mechanisms of type-I- and type-IIinterferon- mediated signalling. Nat Rev Immunol. 2005;5(5):375-386. (Pubitemid 40685987)
20. Katsoulidis E, Sassano A, Majchrzak-Kita B, et al. Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCRABL- expressing cells. J Biol Chem. 2008; 283(16):10793-10803.
21. Gauzzi MC, Barbieri G, Richter MF, et al. The amino-terminal region of Tyk2 sustains the level of interferon alpha receptor 1, a component of the interferon alpha/beta receptor. Proc Natl Acad Sci U S A. 1997;94(22):11839- 11844. (Pubitemid 27467804)
22. Marijanovic Z, Ragimbeau J, Kumar KG, Fuchs SY, Pellegrini S. TYK2 activity promotes ligand-induced IFNAR1 proteolysis. Biochem J. 2006;397(1):31-38. (Pubitemid 44032833)
23. Liu J, HuangFu WC, Kumar KG, et al. Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor. Cell Host Microbe. 2009;5(1):72-83.
24. Goldman LA, Zafari M, Cutrone EC, et al. Characterization of antihuman IFNAR-1 monoclonal antibodies: epitope localization and functional analysis. J Interferon Cytokine Res. 1999;19(1): 15-26. (Pubitemid 29070228)
25. Kumar KG, Krolewski JJ, Fuchs SY. Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor. J Biol Chem. 2004;279(45):46614-46620. (Pubitemid 39518306)
26. Bhattacharya S, HuangFu WC, Liu J, et al. Inducible priming phosphorylation promotes ligandindependent degradation of the IFNAR1 chain of type I interferon receptor. J Biol Chem. 2010; 285(4):2318-2325.
27. Nicolini FE, Hayette S, Legros L, et al. Pegylated IFN-alpha2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone. Leuk Res. 2011; 35(1):80-86.
28. Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363(26):2511- 2521.
29. Yanagisawa K, Yamauchi H, Kaneko M, Kohno H, Hasegawa H, Fujita S. Suppression of cell proliferation and the expression of a bcr-abl fusion gene and apoptotic cell death in a new human chronic myelogenous leukemia cell line, KT-1, by interferon-alpha. Blood. 1998;91(2):641-648. (Pubitemid 28053389)
30. Palandri F, Castagnetti F, Iacobucci I, et al. The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. Haematologica. 2010;95(8):1415-1419.
31. Burchert A, Muller MC, Kostrewa P, et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol. 2010;28(8):1429- 1435.
32. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-1037. (Pubitemid 32267972)
33. Kishi K. A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors. Leuk Res. 1985;9(3):381-390. (Pubitemid 15117022)
34. Kumar KG, Barriere H, Carbone CJ, et al. Sitespecific ubiquitination exposes a linear motif to promote interferon-alpha receptor endocytosis. J Cell Biol. 2007;179(5):935-950. (Pubitemid 350223490)
35. Kumar KG, Tang W, Ravindranath AK, Clark WA, Croze E, Fuchs SY. SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. EMBO J. 2003; 22(20):5480-5490. (Pubitemid 37279957)
36. Liu J, Plotnikov A, Banerjee A, et al. Ligand-independent pathway that controls stability of interferon alpha receptor. Biochem Biophys Res Commun. 2008;367(2):388-393.
37. Zheng H, Qian J, Varghese B, Baker DP, Fuchs SY. Ligand-stimulated downregulation of the interferon alpha receptor: role of protein kinase D2. Mol Cell Biol. 2011;31(4):710-720.
38. Liu J, Carvalho LP, Bhattacharya S, et al. Mammalian casein kinase 1alpha and its leishmanial ortholog regulate stability of IFNAR1 and type I interferon signaling. Mol Cell Biol. 2009;29(24): 6401-6412.
39. Henderson YC, Guo XY, Greenberger J, Deisseroth AB. Potential role of bcr-abl in the activation of JAK1 kinase. Clin Cancer Res. 1997; 3(2):145-149. (Pubitemid 27107287)
40. Mihailovic T, Marx M, Auer A, et al. Protein kinase D2 mediates activation of nuclear factor kappaB by Bcr-Abl in Bcr-Abl- human myeloid leukemia cells. Cancer Res. 2004;64(24):8939-8944. (Pubitemid 39665501)
41. Bossard C, Bresson D, Polishchuk RS, Malhotra V. Dimeric PKD regulates membrane fission to form transport carriers at the TGN. J Cell Biol. 2007;179(6):1123-1131. (Pubitemid 350277732)
42. Messina JL, Yu H, Riker AI, Munster PN, Jove RL, Daud AI. Activated stat-3 in melanoma. Cancer Control. 2008;15(3):196-201.
43. Tamura T, Matsuzaki M, Harada H, Ogawa K, Mohri H, Okubo T. Upregulation of interferon-alpha receptor expression in hydroxyurea-treated leukemia cell lines. J Investig Med. 1997;45(4): 160-167. (Pubitemid 127464836)
44. Barthe C, Mahon FX, Gharbi MJ, et al. Expression of interferon-alpha (IFN-alpha) receptor 2c at diagnosis is associated with cytogenetic response in IFN-alpha-treated chronic myeloid leukemia. Blood. 2001;97(11):3568-3573.
45. Ito K, Tanaka H, Ito T, et al. Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34- positive cells and its down-regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia. Eur J Haematol. 2004;73(3):191-205. (Pubitemid 39062243)
46. Evans IM, Bagherzadeh A, Charles M, et al. Characterization of the biological effects of a novel protein kinase D inhibitor in endothelial cells. Biochem J. 2010;429(3):565-572.
47. Monovich L, Vega RB, Meredith E, et al. A novel kinase inhibitor establishes a predominant role for protein kinase D as a cardiac class IIa histone deacetylase kinase. FEBS Lett. 2010;584(3):631- 637.
48. Lavalle CR, Bravo-Altamirano K, Giridhar KV, et al. Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility. BMC Chem Biol. 2010;10:5.
49. Harikumar KB, Kunnumakkara AB, Ochi N, et al. A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther. 2010;9(5):1136-1146.
50. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401-412.